BridgeBio Oncology Therapeutics, Inc.
BBOT
$7.40
-$0.29-3.77%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 19.55% | -62.25% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 6.38% | -11.74% | |||
| Operating Income | -6.38% | 11.74% | |||
| Income Before Tax | -8.53% | 13.32% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -8.53% | 13.32% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -8.53% | 13.32% | |||
| EBIT | -6.38% | 11.74% | |||
| EBITDA | -6.42% | 11.78% | |||
| EPS Basic | -8.47% | 52.87% | |||
| Normalized Basic EPS | -8.48% | 52.88% | |||
| EPS Diluted | -8.47% | 52.87% | |||
| Normalized Diluted EPS | -8.48% | 52.88% | |||
| Average Basic Shares Outstanding | 0.06% | 83.92% | |||
| Average Diluted Shares Outstanding | 0.06% | 83.92% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||